Treatment of Neuroleptic Induced Acute Akathisia With Trazodone
SchizophreniaAdministration of trazodone for the treatment of neuroleptic induced acute akathisia in a cross-over fashion of 6 days duration. 3 days of placebo and 3 days of trazodone.
Efficacy of Pregnenolone in Patients With Schizophrenia
SchizophreniaSchizoaffective DisorderFour-month trial of pregnenolone or placebo, as an additional medication, to treat negative symptoms and cognitive decline in schizophrenia. After four months the scores on the negative symptom scale should be lower and the scores on the cognitive tests should be higher than they were at study entry, compared with people who do not take any additional medication.
Patient-reported Outcomes in the Treatment of Schizophrenia
SchizophreniaPatient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete...
SchizophreniaSchizoaffective DisorderAs many as 75 percent of patients with schizophrenia have difficulty taking their oral medication on a regular basis. This may lead to worsening of symptoms. Clinicians commonly respond to these problems by adding adjunctive medications, despite the absence of systematic studies that support such practices. It is possible, however, that in many of these cases, the unstable course and/or unsatisfactory treatment response reflects incomplete adherence with the originally prescribed oral antipsychotic, rather than a need for adjunctive medications. This study will examine whether switching patients who demonstrate an unstable course and/or an unsatisfactory clinical response to a long-acting injectable preparation as the primary antipsychotic may enhance medication adherence and improve outcomes.
Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition...
SchizophreniaSchizoaffective DisorderThe major objective of this proposal is to test the hypothesis that the addition of divalproex sodium to an atypical antipsychotic drug other than clozapine will significantly improve: a) cognition; and b) psychopathology (positive, negative, and mood symptoms) in a double-blind, randomized trial of 6 weeks duration in patients with schizophrenia or schizoaffective disorder.
Health Evaluation of Abilify Long-term Therapy
SchizophreniaSchizoaffective DisorderThis is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment. The health profiles during the switching period, after 12 weeks short-term use, and after 52 weeks long-term use of aripiprazole will be recorded and evaluated.
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
SchizophreniaA study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) in...
SchizophreniaThere is pilot data to suggest the therapeutic value of rTMS applied to the left prefrontal cortex in the treatment of negative symptoms. Neuroimaging studies demonstrate abnormal activity in this region in patients experiencing negative symptoms. Finally rTMS applied at high frequency shows the capacity to up-regulate cortical activity in a way that would provide an explanation for a therapeutic response. The study involves participants receiving 15 sessions of high frequency rTMS treatment applied bilaterally to the prefrontal cortex over a 3 week period or sham rTMS. Following this double blind phase, participants randomised to placebo treatment will be offered 15 sessions of active treatment. In addition, ppTMS (paired pulse TMS) will be conducted prior to the onset of treatment and after completion of the course, as a means of measuring cortical inhibition and facilitation. NIRS (Near Infra red spectroscopy) will also be conducted prior to, during and after the first and last treatment sessions to allow monitoring of oxygenated and deoxygenated haemoglobin.
Glycine vs Placebo for the Schizophrenia Prodrome
Schizophrenia ProdromeGlycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder...
SchizophreniaSchizoaffective DisorderThis study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.